insights_auto
Hvorfor har ALNY gått ned? 4,96%?
GÃ¥ mer i dybdenchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
219,72Â USD
arrow_downward
−4,96%(−11,46) 1 D
2. okt., 16:00:01 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for ALNY …
Ã…pne
231,31Â USD
Høy
231,36Â USD
Lav
219,40Â USD
Markedsverdi
29,40Â mrd.
Snittvolum
1,55Â mill.
Volum
0,00
P/E-forhold
37,40
52 u høy
495,55Â USD
52Â u lav
197,81Â USD
EPS
5,88Â USD
Beta
0,28
Utestående aksjer
133,81Â mill.
Antall ansatte
2k
Ã…pne
231,31Â USD
Høy
231,36Â USD
Lav
219,40Â USD
Markedsverdi
29,40Â mrd.
Snittvolum
1,55Â mill.
Volum
0,00
P/E-forhold
37,40
52 u høy
495,55Â USD
52Â u lav
197,81Â USD
EPS
5,88Â USD
Beta
0,28
Utestående aksjer
133,81Â mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Simply Wall Street
·
for 3 døgn siden
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Om Alnylam Pharmaceuticals, Inc.